Isturisa (Osilodrostat)

Isturisa is a cortisol synthesis inhibitor used for the treatment of adult patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative. 

Recommended Dosage: Initiate Isturisa dosing at 2 mg orally twice a day, with or without food. Initially, titrate the dosage by 1-2 mg twice a day, no more frequently than every 2 weeks on behalf of the rate of cortisol changes, individual tolerability and improvement in signs and symptoms of Cushing’s disease. If a patient tolerates dosage of 10 mg twice a day and continues to have elevated 24-hour urine free cortisol (UFC) levels more than upper normal limit, the dosage may be titrated further by 5 mg twice a day every 2 weeks. 

The maintenance dosage of Isturisa is individualized and specified by titration on behalf of the cortisol levels and patient’s signs/symptoms. The maintenance dosage of isturisa tablets varied between 2 mg and 7 mg twice daily in clinical trials. The maximum recommended maintenance dosage of Isturisa is 30 mg twice a day. Once the maintenance dosage is achieved, monitor cortisol levels at least every 30 to 60 days or as indicated.

• Cortisol levels should be monitored from at least two 24-hour urine free cortisol collections every 1 to 2 weeks until adequate clinical response is maintained.
• Treatment with isturisa 10 mg or any other dosage strength typically lowers cortisol levels and may lead to hypocortisolism and sometimes severe adrenal insufficiency. Patients should be educated on the symptoms associated with hypocortisolism and should contact a doctor if they occur.
• Treatment with isturisa 5 mg or other dosage strength is associated with a dose-dependent QT interval prolongation, which can cause cardiac arrhythmias. Caution should be used in patients with risk factors for QT prolongation, and consider a bit more frequent ECG monitoring.
• Advise respective females not to breastfeed their child during treatment with Isturisa 1 mg / 5 mg / 10 mg and for at least seven days after treatment. 
• Hypokalemia and hypomagnesemia needs to be corrected prior to starting Osilodrostat. Obtain baseline ECG (electrocardiogram). Repeat ECG within 7 days after initiation of treatment. 

What documents are required to import ISTURISA to India?

ISTURISA (Osilodrostat) tablets can be imported by patients or government hospitals on the name of the patients only. 

The following documentation required to import the product:

• Valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patients Identity Proof (issued by government of India)

How does order be confirmed?

The order will be confirmed only after the receipt of:

• Valid prescription of Doctor
• Import permit if applicable

Is ISTURISA available in India?

ISTURISA (osilodrostat tablets) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is facilitator providing input

• On availability in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore and Pune etc.)
• Medicine Price.
• Finding Genuine and reliable source from Canada, Europe, USA and Australia
• Ensuring 100% transparency.

ISTURISA can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.

IPN (Indian Pharma Network) can facilitate the supply of ISTURISA (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)

Please contact +91-9310090915 | Toll-Free No: 1800-889-1064 or write us at info@indianpharmanetwork.in for osilodrostat price in India. 

We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network is able to source ISTURISA (Cancer Treatment Medicines) from across the globe, and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Isturisa®?

Osilodrostat is Generic Name for the trade name drug Isturisa®.

What is the Manufacturer Name of Isturisa®?

Isturisa® is manufactured by Recordati Rare Diseases, Inc. 

Is Isturisa® approved by the FDA?

Yes, Isturisa® is approved by the FDA. Date of approval: March 06, 2020.

What is Isturisa®?

Isturisa® (Osilodrostat) is the first cortisol synthesis inhibitor aimed to treat Cushing’s disease on patients who can’t have pituitary surgery, or who have had the pituitary surgery, but the surgery was not effective gor their Cushing’s disease.

What is the dosage and form of Isturisa® supplied?

Isturisa® is supplied as Tablets: 1 mg, 5 mg, and 10 mg for oral administration. 

What are the most common side effects due to Isturisa®? 

Most common side effects due to Isturisa® include: edema, adrenal insufficiency, fatigue, nausea, and headache. 

How much does Isturisa® cost in India?

The isturisa cost in India is absolutely reasonable. In order to procure this Cushing’s disease medicine authentically, you can call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

What are the storage conditions of Isturisa®?

Store the tablets of Isturisa at temperature between 68°F to 77°F (20°C to 25°C); excursions permitted 15°C to 30°C (59°F to 86°F). Protect the tablets from moisture.

What are the Highlights of prescribing information for Isturisa®?

Click Here to download full Isturisa prescribing information.